{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-037852","form_type":"8-K","ticker":null,"cik":"0001100397","company_name":"Ayala Pharmaceuticals, Inc.","filed_at":"2023-10-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.219876+00:00","generated_at":"2026-06-09T18:02:43.645972+00:00","sec_items":["2.01","3.02","5.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ayala Pharmaceuticals closes merger with Biosight, adds AML drug aspacytarabine","bullets":["Merger completed Oct 18, 2023; ~5.9M Ayala shares issued to former Biosight holders at 1.82285 exchange ratio.","Pipeline expands: adds aspacytarabine (BST-236) for AML; Phase 3 AL102 for desmoid tumors continues.","Roy Golan appointed CFO, replacing interim CFO Igor Gitelman, effective at closing.","Board changes: Dr. Samir Khleif resigned; new directors Yuval Cabilly, Pini Orbach, Bridget Martell appointed.","Combined company continues on OTCQX under ticker ADXS."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-037852","json":"https://secwatch.observer/filing/0001493152-23-037852.json","markdown":"https://secwatch.observer/filing/0001493152-23-037852.md","text":"https://secwatch.observer/filing/0001493152-23-037852.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T18:02:43.645972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08710fb980","claim":"Bridget Martell was appointed as Director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Bridget Martell, M.D.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"19ede9a144","claim":"Samir Khleif resigned as Director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"immediately prior to the Effective Time, Dr. Samir Khleif resigned from the Board of the Registrant.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"450bd266e5","claim":"Roy Golan was appointed as Chief Financial Officer at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Effective as of the Effective Time, Roy Golan, CPA, LLM, will become the Registrant’s Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"699cfa61d4","claim":"Yuval Cabilly was appointed as Director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Yuval Cabilly, Ph.D .","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"6c7223e609","claim":"Igor Gitelman departed as Interim Chief Financial Officer at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Igor Gitelman will cease to serve as the Company’s Interim Chief Financial Officer at that time.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"ceased to serve"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f116516c22","claim":"Pini Orbach was appointed as Director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Pini Orbach, Ph.D .","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"39c87d2d4e25f20dbd53b2b289df0ddda5b316b5","claim":"Ayala Pharmaceuticals, Inc. completed an acquisition involving Biosight Ltd. (closed 2023-10-18).","evidence_excerpt":"On October 18, 2023 (the “Closing Date”), pursuant to the Merger Agreement, Merger Sub consummated the merger with and into Biosight, with Biosight continuing as the surviving company and a wholly-owned subsidiary of the Registrant (the “Merger”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315223037852/0001493152-23-037852-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Biosight Ltd."},{"label":"Closing","value":"2023-10-18"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}